Phase III data show that the experimental integrase inhibitor dolutegravir, a combined effort from GlaxoSmithKline, Pfizer and Shionogi, fully suppressed viral loads among 63 percent of people with multi drug-resistant HIV, Bloomberg reports. Announcing the results of their joint VIKING-3 study at the 11th International Congress on Drug Therapy in HIV Infection in Glasgow, ViiV Healthcare said this third of four late-stage trials of dolutegravir sets the stage for regulatory filing by the end of the year.

ViiV tested the dolutegravir in 183 people with multiple antiretroviral (ARV) class resistance, including resistance to other integrase inhibitors—raltegravir and/or elvitegravir. After 24 weeks, 63 percent achieved an undetectable viral load, with only 3 percent discontinuing because of side effects. The most common side effects, each occurring in 5 percent of patients, included diarrhea, nausea and headache.

To read the Bloomberg article, click here.

To read the ViiV press release, click here.